Bicycle Therapeutics (BCYC) Fundamental Analysis: Revenue, Earnings & Valuation

3.79 / 10

Netural

Fundamental assessment scores 3.8/10, reflecting inadequate conditions. Strengths include solid fixed‑asset turnover and strong interest‑coverage ratios. Weaknesses arise from poor income‑tax‑to‑profit ratio and stagnant YoY revenue growth. Overall, fundamentals are mixed but lean toward negative.

Analysis Checks(6/10)

Revenue-MV

Value-0.49

Score1/3

Weight20.08%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value105.77

Score1/3

Weight-4.62%

1M Return-1.40%

Inventory turnover ratio

Value106.57

Score3/3

Weight-2.15%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score3/3

Weight7.79%

1M Return2.33%

PB-ROE

Value-0.38

Score3/3

Weight54.81%

1M Return12.56%

Income tax / Total profit (%)

Value-0.07

Score1/3

Weight-1.95%

1M Return-0.59%

Fixed assets turnover ratio

Value3.71

Score2/3

Weight-3.40%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.40%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-2.36%

1M Return-0.74%

Asset-MV

Value-0.55

Score1/3

Weight34.20%

1M Return7.28%

Is BCYC undervalued or overvalued?

BCYC scores 3.79/10 on fundamentals and holds a Fair valuation at present. Backed by its -31.21% ROE, -301.66% net margin, -1.50 P/E ratio, 0.54 P/B ratio, and -8.97% earnings growth, these metrics solidify its Netural investment rating.